Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis.

British journal of clinical pharmacology·2026
Same author

Posaconazole in Saliva: Feasibility of a Noninvasive Monitoring Approach in Immunocompromised Children.

The Pediatric infectious disease journal·2026
Same author

Modeling amyloid plaque turnover dynamics improves characterization of drug effects.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Letter to the Editor: Lean-Body Mass-Guided Heparin Dosing: A Pharmacokinetic Imperative.

Hospital pharmacy·2025
Same author

Personalized tobramycin dosing in children with cystic fibrosis: an AUC<sub>24</sub>-guided approach.

Antimicrobial agents and chemotherapy·2025
Same author

The accessory type III secretion system effectors collectively shape intestinal inflammatory infection outcomes.

Gut microbes·2025
Same journal

Reed diffusers: a potential cause of poisoning in young children in New Zealand.

The New Zealand medical journal·2026
Same journal

Stuffy nights: elevated bedroom carbon dioxide concentrations indicate inadequate ventilation in Wellington homes.

The New Zealand medical journal·2026
Same journal

Cautionary tale of how sodium polystyrene sulfonate caused gut necrosis: a case report.

The New Zealand medical journal·2026
Same journal

Emergency lateral canthotomy and cantholysis for acute globe subluxation.

The New Zealand medical journal·2026
Same journal

Liberation of an incarcerated tibialis posterior tendon following a posterior malleolar ankle fracture: a case report.

The New Zealand medical journal·2026
Same journal

Implementing a cultural safety training plan across medical colleges in Aotearoa New Zealand-looking back, and looking forward.

The New Zealand medical journal·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Current enoxaparin dosing guidelines have dubious credibility.

Hesham Al-Sallami1, Sarah Jordan, Ruth Ferguson

  • 1School of Pharmacy, University of Otago, PO Box 56, Dunedin, New Zealand. hesham.al-sallami@otago.ac.nz

The New Zealand Medical Journal
|June 29, 2010
PubMed
Summary
This summary is machine-generated.

Enoxaparin dosing guidelines are too simple, leading to incorrect prescribing in 30.7% of cases. This study highlights discrepancies between recommended and actual enoxaparin doses in clinical practice.

Related Experiment Videos

Last Updated: Jun 11, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Evidence-Based Medicine

Background:

  • Enoxaparin is a widely used low-molecular-weight heparin for thrombosis treatment.
  • Accurate dosing is crucial for efficacy and safety.
  • Existing dosing guidelines aim to standardize enoxaparin prescription.

Purpose of the Study:

  • To evaluate the adherence to enoxaparin dosing guidelines in a clinical setting.
  • To identify prescribing patterns and deviations from recommended enoxaparin doses.

Main Methods:

  • Prospective observational chart review at Dunedin Public Hospital.
  • Inclusion of patients receiving enoxaparin for thrombosis treatment.
  • Data collection on dose deviations, patient weight, and creatinine clearance.

Main Results:

  • 30.7% of enoxaparin administrations showed dose deviations from guidelines.
  • Dose discrepancies were more frequent near guideline transition points (e.g., weight >90 kg, CrCl 20-40 mL/min).

Conclusions:

  • Current enoxaparin dosing guidelines are overly simplistic.
  • The guidelines contribute to a discordance between prescribed and approved enoxaparin doses.
  • Clinical practice may require more nuanced dosing recommendations.